Home
Search
Search Only:

Search Keyword tysabri

Total: 30 results found.

Page 1 of 2
Biogen Idec Inc. disclosed five more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. bringing the total number of cases to 63 as of Aug. 4. The ...
Abstract It has been suggested that natalizumab-associated progressive multifocal leukoencephalopathy may be prevented by structured interruptions of treatment. Evidence supporting such a drug holiday ...
... Tysabri. Thirty percent of physicians surveyed fall into the high-volume, cost-conscious prescriber segment, and value out-of-pocket cost to the patient and reimbursement restrictions more than the other ...
Biogen Idec Inc. disclosed three more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp., bringing the total number of cases to 58 as of July 2. The ...
... MS (RRMS) patients, as it becomes the world's first oral disease-modifying MS therapy to be granted marketing authorization beating Novartis's Gilenia(fingolimod). Without Tysabri and Extavia launching, ...
... infection, presumably a result of immune suppression. Other biologic drugs targeting immune system components have been linked to PML, as well, including natalizumab (Tysabri) and efalizumab (Raptiva). Both ...
At least one more patient has been diagnosed with a rare, and potentially fatal brain infection after taking natalizumab (Tysabri), the hit drug for multiple sclerosis from Biogen Idec and Elan, according ...
Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS) who may benefit from, or are receiving treatment with Tysabri® (natalizumab) were published today ...
... death or severe disability) among people who have used Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) after it became available for prescription in July 2006. As of the end of September ...
... management program for its leading multiple sclerosis drug Tysabri is the example the FDA uses as the gold standard for REMS. Biogen has obtained ex-US rights to Fampridine-SR and Elan receives seven percent ...
Different methods of weighing the risks and benefits of medical treatments lead to varying conclusions about their safety Ever since the powerful multiple sclerosis drug Tysabri returned to the market ...
An 11th patient taking Biogen Idec Inc's multiple sclerosis drug Tysabri has developed a potentially deadly brain infection since July 2006, when it was reintroduced to the market. The Cambridge, ...
... they also didn't get any worse, Burt notes. The next critical step is to figure out how the stem cell therapy stacks up against existing treatments for MS, such as tysabri and novantrone. These meds ...
Biogen Idec Inc. reported that a ninth patient on its multiple sclerosis drug Tysabri, sold with Elan PLC, has developed a rare brain infection, the third such report since mid-May. A suspected link ...
Biogen Idec Inc. said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year. The patient was confirmed ...
... reported by patients on therapy, further demonstrate the benefits of TYSABRI in treating MS and are helping to redefine successful treatment of the disease. The study, which was performed in conjunction ...
... presented the latest usage and safety statistics for [[Tysabri]] (Biogen Idec and Elan Pharmaceuticals), which in the U.S. is approved for administration to people with relapsing-remitting MS through the ...
... of the patients used [[Avonex]] as index medication, while others used [[Copaxone]] (31 percent), [[Rebif]] (17 percent), [[Betaseron]] (14 percent) and [[Tysabri]] (less than 1 percent). Source: Lori ...
... these drugs are most effective if started within 48 hours of onset of symptoms. Should injectable MS therapies or Tysabri be discontinued? No. You should continue to follow your physician’s treatment ...
Biogen Idec’s Tysabri will play a significant role in the second line setting for the treatment of [[relapsing-remitting]] multiple sclerosis (MS), despite looming competition from new oral agents in development, ...
«StartPrev12NextEnd»